20,568 Shares in Medtronic PLC $MDT Purchased by Tema Etfs LLC

Tema Etfs LLC acquired a new stake in Medtronic PLC (NYSE:MDT) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 20,568 shares of the medical technology company’s stock, valued at approximately $1,793,000.

Several other hedge funds have also modified their holdings of the business. Amundi boosted its stake in shares of Medtronic by 18.8% during the 2nd quarter. Amundi now owns 5,077,104 shares of the medical technology company’s stock worth $448,207,000 after acquiring an additional 803,584 shares in the last quarter. M Holdings Securities Inc. acquired a new stake in Medtronic during the second quarter worth approximately $995,000. Marshall Wace LLP boosted its holdings in shares of Medtronic by 3,424.7% during the second quarter. Marshall Wace LLP now owns 160,374 shares of the medical technology company’s stock worth $13,980,000 after purchasing an additional 155,824 shares during the last quarter. Beutel Goodman & Co Ltd. grew its holdings in Medtronic by 2.4% in the 2nd quarter. Beutel Goodman & Co Ltd. now owns 4,907,266 shares of the medical technology company’s stock valued at $427,766,000 after buying an additional 115,209 shares during the period. Finally, Dodge & Cox increased its position in Medtronic by 0.4% during the second quarter. Dodge & Cox now owns 7,740,383 shares of the medical technology company’s stock worth $674,729,000 after purchasing an additional 31,550 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Performance

Shares of MDT stock opened at $101.93 on Friday. The stock’s fifty day simple moving average is $96.65 and its 200-day simple moving average is $92.08. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $130.68 billion, a price-to-earnings ratio of 27.47, a P/E/G ratio of 2.69 and a beta of 0.71. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the previous year, the company earned $1.26 earnings per share. The company’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, December 26th. Medtronic’s dividend payout ratio is presently 76.55%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Medtronic in a research report on Tuesday. Barclays lifted their price objective on Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, November 20th. JPMorgan Chase & Co. increased their price target on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Finally, Royal Bank Of Canada upped their target price on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $110.44.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.